Lilly widens early-access for unapproved obesity drug retatrutide
TL;DR Summary
Eli Lilly says it will allow more patients to apply for pre-approval access to retatrutide, the unapproved obesity drug, after previously granting access to a single 79‑year‑old patient; the company is reviewing requests from doctors in line with FDA guidance.
- Eli Lilly to allow more patients to apply for special access to unapproved obesity drug STAT
- Eli Lilly to offer early access to next-gen obesity drug to some patients Reuters
- Spotlight On: Good news and bad news for Lilly's triple agonist FirstWord Pharma
- Retta Weight Loss: The Evidence, Benefits, and Realistic Expectations - View QMQEr6GEs FC Bayern
- This Next-Gen GLP-1 Is Blowing Up the Black Market Economy Marie Claire
Reading Insights
Total Reads
1
Unique Readers
4
Time Saved
3 min
vs 3 min read
Condensed
93%
579 → 40 words
Want the full story? Read the original article
Read on STAT